Journal of Diabetes Research / 2016 / Article / Tab 2

Clinical Study

Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial

Table 2

Glycemic outcomes.

Baseline, mean ± SDEnd of study, mean ± SDDifference from baseline, MDC (95% CI, )
CGM pre-CSIICGM post-CSIICGM pre-CSIICGM post-CSIICGM pre-CSIICGM post-CSII

, %0.920.90 (−1.18, ; ) (−1.02, −0.11; )
Average interstitial glucose, mg/dL0.720.31 (, ; ) (−48, −2; )
% capillary glucose levels <70 mg/dL0.600.03 (, ; ) (, 16; )
% capillary glucose levels >180 mg/dL0.060.477.0 (.4, 5.4; )11.4 (, 40.1; )
Average AUC <70 mg/dL/day0.350.01 (, ; ) (, 0.6; )
Average AUC >180 mg/dL/day0.670.42 (, ; ) (, ; )
Severe hypoglycemia events0.710.03 (, ; ) (, 1.0; )

RT-CGM pre-CSII: real-time continuous glucose monitoring before continuous subcutaneous insulin infusion; RT-CGM post-CSII: real-time continuous glucose monitoring after continuous subcutaneous insulin infusion; MDC: mean difference in change; CI: confidence interval.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.